MannKind reported $-55042000 in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.


Equity Capital And Reserves Change Date
Adma Biologics USD 398.32M 49.3M Jun/2025
Dynavax Technologies USD 494.16M 36.78M Jun/2025
Eli Lilly USD 18.27B 2.43B Jun/2025
Halozyme Therapeutics USD 332.75M 149.52M Jun/2025
Insmed USD 1.25B 1.15B Jun/2025
MacroGenics USD 46.62M 69.44M Jun/2025
MannKind USD -55042000 3.58M Jun/2025
Merck USD 49.06B 725M Jun/2025
Novo Nordisk DKK 138.54B 18.02B Mar/2025
Pfizer USD 88.7B 1.64B Jun/2025
Sanofi 70.28B 3.8B Jun/2025
Xencor USD 620.35M 19.52M Jun/2025